EU authorises use of remdesivir to treat coronavirus

covid-19
Credit: CC0 Public Domain

The European Commission, the bloc's executive arm, on Friday authorised the use of anti-viral drug remdesivir to treat the new coronavirus.

"Today's authorisation of a first medicine to treat COVID-19 is an important step forward in the fight against this virus," EU Health Commissioner Stella Kyriakides said in a statement.

"We are granting this authorisation less than a month after the application was submitted, showing clearly the EU's determination to respond quickly whenever new treatments become available," she said.

At least two major US studies have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.

Washington authorised the emergency use of the —which was originally intended as a treatment for Ebola—on May 1, followed by several Asian nations including Japan and South Korea.

The comes on the recomendation of the European Medicines Agency which gave its conditional authorisation last week for the treatment of patients above 12 years of age who are suffering pneumonia and require extra oxygen.

It said its assessment was based mainly based on data from a study sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID).

The research, published in the leading journal the New England Journal of Medicine in May, showed that injections of remdesivir speeded patient recovery compared with a placebo.

On average it reduced patients' hospital stays from 15 days to 11.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

Journal information: New England Journal of Medicine

© 2020 AFP

Citation: EU authorises use of remdesivir to treat coronavirus (2020, July 3) retrieved 25 September 2020 from https://medicalxpress.com/news/2020-07-eu-authorises-remdesivir-coronavirus.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments